From: Hypnotics and injuries among older adults with Parkinson’s disease: a nested case–control design
Injury | |||||||
---|---|---|---|---|---|---|---|
Yes | (%) | No | (%) | P | Total | ||
3343 | (66.7) | 1666 | (33.3) | 5009 | |||
Benzodiazepines | 0.000 | ||||||
Yes | 110 | (53.4) | 96 | (46.6) | 206 | ||
No | 3233 | (67.3) | 1570 | (32.7) | 4803 | ||
Non-benzodiazepines | 0.000 | ||||||
Yes | 99 | (47.8) | 108 | (52.2) | 207 | ||
No | 3244 | (67.6) | 1558 | (32.4) | 4802 | ||
Melatonin receptor agonists | 0.009 | ||||||
Yes | 43 | (53.1) | 38 | (46.9) | 81 | ||
No | 3300 | (67.0) | 1628 | (33.0) | 4928 | ||
Orexin receptor antagonists | 0.000 | ||||||
Yes | 43 | (43.4) | 56 | (56.6) | 99 | ||
No | 3300 | (67.2) | 1610 | (32.8) | 4910 | ||
Fracture | |||||||
Yes | (%) | No | (%) | P | Total | ||
1894 | (37.8) | 3115 | (62.2) | 5009 | |||
Benzodiazepines | 0.000 | ||||||
Yes | 67 | (23.3) | 221 | (76.7) | 288 | ||
No | 1827 | (38.7) | 2894 | (61.3) | 4721 | ||
Non-benzodiazepines | 0.000 | ||||||
Yes | 67 | (24.3) | 209 | (75.7) | 276 | ||
No | 1827 | (38.6) | 2906 | (61.4) | 4733 | ||
Melatonin receptor agonists | 0.000 | ||||||
Yes | 29 | (22.0) | 103 | (78.0) | 132 | ||
No | 1865 | (38.2) | 3012 | (61.8) | 4877 | ||
Orexin receptor antagonists | 0.000 | ||||||
Yes | 30 | (19.4) | 125 | (80.6) | 155 | ||
No | 1864 | (38.4) | 2990 | (61.6) | 4854 | ||
Femoral fracture | |||||||
Yes | (%) | No | (%) | P | Total | ||
512 | (10.2) | 4497 | (89.8) | 5009 | |||
Benzodiazepines | 0.007 | ||||||
Yes | 24 | (6.2) | 362 | (93.8) | 386 | ||
No | 488 | (10.6) | 4135 | (89.4) | 4623 | ||
Non-benzodiazepines | 0.008 | ||||||
Yes | 23 | (6.2) | 347 | (93.8) | 370 | ||
No | 489 | (10.5) | 4150 | (89.5) | 4639 | ||
Melatonin receptor agonists | 0.109 | ||||||
Yes | 12 | (6.7) | 168 | (93.3) | 180 | ||
No | 500 | (10.4) | 4329 | (89.6) | 4829 | ||
Orexin receptor antagonists | 0.009 | ||||||
Yes | 10 | (4.8) | 197 | (95.2) | 207 | ||
No | 502 | (10.5) | 4300 | (89.5) | 4802 |